由德国传染病学会(DGI)领导的国际专家团队在《自然·医学》期刊上发布了首个协调一致的个性化噬菌体疗法临床指南 1。该指南旨在规范利用病毒对抗抗生素耐药细菌的治疗实践,涵盖了超过60项具体建议,内容涉及噬菌体的选择、测试、制造、给药及监测等全流程 1。这项举措汇聚了20个专业组织和18位国际专家的智慧,Annika Claßen博士作为主要制定者之一参与了起草工作,Silvia Würstle博士担任通讯作者 1。指南的有效期设定为2026年1月5日至2030年6月29日 1。
新指南主要针对铜绿假单胞菌和金黄色葡萄球菌这两类病原体 1。早期临床数据显示出积极效果:在比利时一项包含100名患者的病例研究中,77%的患者临床状况得到改善,61%的目标细菌检测不到 1。此外,法兰克福大学医学中心自2026年2月以来,已依据新指南成功治疗了十名患者 1。
An international team of experts led by the German Society for Infectious Diseases (DGI) has released the first coordinated clinical guidelines for personalized phage therapy, a treatment approach that utilizes viruses to fight antibiotic-resistant bacteria 1. Published in Nature Medicine, the document involves contributions from 20 professional organizations and 18 international experts, aiming to standardize practices across various stages of treatment, including phage selection, testing, manufacturing, administration, and monitoring 1. The guidelines comprise more than 60 specific recommendations and will remain in effect from January 5, 2026, through June 29, 2030 1. Key figures involved in the development include Annika Claßen, Ph.D., as one of the primary drafters, and Silvia Würstle, Ph.D., serving as the corresponding author 1.
The new protocols primarily target dangerous pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus 1. Early data supports the efficacy of this approach; in a Belgian case series involving 100 patients, 77% showed clinical improvement while 61% had their target bacteria become undetectable 1. Furthermore, the University Hospital Frankfurt has successfully treated ten patients according to these new guidelines since February 2026 1.
评论
还没有评论,欢迎留下第一条。